SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 8, 2003
GUILFORD PHARMACEUTICALS INC.
(Exact name of registrant as specified in its
charter)| | | | | |
| Delaware | | 0-23736 | | 52-1841960 |
| |
| |
|
| (State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer
Identification No.) |
| | | |
6611 Tributary Street
Baltimore, Maryland
(Address of principal executive offices) | | 21224
(Zip Code) |
Registrant’s telephone number, including area code: (410) 631-6300
(Former name or former address, if changed since last report)
Exhibit Index is on page 4.
INFORMATION TO BE INCLUDED IN THE REPORT
Item 9. Regulation FD Disclosure (Information Provided Under Item 12 Results of Operations and Financial Condition)
The following information is furnished pursuant to Item 12, “Results of Operations and Financial Condition.”
On May 8, 2003, Guilford Pharmaceuticals Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2003. A copy of Guilford Pharmaceuticals Inc.’s press release is furnished as Exhibit 99.1 to this report.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | GUILFORD PHARMACEUTICALS INC |
| |
| |
| Dated: May 8, 2003 | By: | /s/ Andrew R. Jordan
Andrew R. Jordan |
| | | Executive Vice President, Chief Financial Officer, and Treasurer (Principal Financial Officer and Principal Accounting Officer) |
-3-
INDEX TO EXHIBITS
| | | | | | | |
| Exhibit | | | | | | |
| Number | | Exhibit Description | | Page |
| |
| |
|
| 99.1 | | Press Release dated May 8, 2003, issued by Guilford Pharmaceuticals Inc. | | | 5 | |
-4-
